EUVIMEDEUVIMED entdecken
Crossref

Optimizing the diagnosis of chronic granulomatous disease using dihydrorhodamine‐123 assay: Lessons from a large monocentric cohort

Lodoeva Oiuna iD, Varlamova Tatiana iD, Yukhacheva Daria iD, Vedmedskaia Viktoriia iD, Fadeeva Mariia iD, Kulakovskaya Elena iD, Malakhova Ekaterina iD, Musaeva Elvira iD, Samykina Elizaveta iD, Sozonova Tatiana, Glushkova Svetlana, Igonina Mariia und 9 weitere

Cytometry Part B: Clinical Cytometry · 2026

DOI: 10.1002/cytob.70014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2026. Verfasst von Lodoeva Oiuna und 20 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Transplantation Immunology and Immunotherapy, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Im…. Hauptthemen laut MEDLINE: Granulomatous Disease, Chronic, Rhodamines, Flow Cytometry. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The dihydrorhodamine‐123 flow cytometry (DHR FC) assay is used to diagnose chronic granulomatous disease (CGD). This study presents the experience of a single center with the DHR FC assay in a large cohort to evaluate its applications and limitations. A total of 179 subjects were included in the study for CGD diagnosis, X‐linked CGD (X‐CGD) carrier determination, and post‐hematopoietic stem cell transplantation (HSCT) chimerism monitoring. We performed the DHR FC assay using a standardized protocol, with additional intracellular myeloperoxidase (MPO) staining for borderline cases. The DHR FC assay demonstrated high diagnostic accuracy. PMA stimulation detected 94% of CGD cases. E. coli stimulation identified all CGD cases, including atypical EROS‐deficient ( CYBC1 ) patients (4.3% of the cohort) who exhibited residual reactive oxygen species production (median SI PMA = 40 vs. E. coli = 24). Genetic confirmation revealed that 82% of CGD patients had X‐CGD ( CYBB ), and 18% had autosomal recessive CGD ( CYBA / NCF1 / NCF2 / CYBC1 ) forms. Borderline results were clarified by MPO staining, which diagnosed three MPO‐deficient cases. The assay reliably identified 43 X‐CGD carriers out of 45 suspected cases and showed a strong correlation with the real‐time quantitative polymerase chain reaction for HSCT chimerism monitoring ( r = 0.78, p < 0.0001). The DHR FC assay is a rapid and reliable diagnostic tool for CGD, providing results within hours. Its applications extend to X‐CGD carrier detection and post‐HSCT chimerism monitoring. Dual‐stimulant protocols (PMA + E. coli ) and MPO staining enhance diagnostic accuracy. These findings support the use of the DHR FC assay as a versatile and essential tool in CGD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulomatous Disease, ChronicRhodaminesFlow CytometryHumansFemaleChildChild, PreschoolMaleHematopoietic Stem Cell TransplantationPeroxidaseCohort StudiesInfantAdolescentNADPH Oxidases

Stichwörter der Autor:innen

chronic granulomatous diseasedihydrorhodamine‐123 assayinborn errors of immunitymyeloperoxidase deficiency

Substanzen

dihydrorhodamine 123RhodaminesPeroxidaseNADPH Oxidases

Autor:innen und Institutionen

  • Laboratory of Transplantation Immunology and Immunotherapy, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Laboratory of Molecular Biology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Department of Immunology, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
  • Russian Children Clinical Hospital, N.I. Pirogov National Research Medical University, Moscow, Russia.
  • Department of Hematopoietic Stem Cell Transplantation, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.

ORCID-Profile: Lodoeva Oiuna, Varlamova Tatiana, Yukhacheva Daria, Vedmedskaia Viktoriia, Fadeeva Mariia, Kulakovskaya Elena, Malakhova Ekaterina, Musaeva Elvira, Samykina Elizaveta, Russiyanov Andrey, Brilliantova Varvara, Alexenko Maxim, Vahliarskaya Svetlana, Raykina Elena, Maschan Michael, Shcherbina Anna, Pershin Dmitry

Zitieren

APA

Oiuna, L., Tatiana, V., Daria, Y., Viktoriia, V., Mariia, F., Elena, K., Ekaterina, M., Elvira, M., Elizaveta, S., Tatiana, S., Svetlana, G., Mariia, I., Andrey, R., Varvara, B., Maxim, A., Svetlana, V., Elena, R., Yulia, R., Michael, M., …, & Dmitry, P. (2026). Optimizing the diagnosis of chronic granulomatous disease using dihydrorhodamine‐123 assay: Lessons from a large monocentric cohort. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cytob.70014

Vancouver

Oiuna L, Tatiana V, Daria Y, Viktoriia V, Mariia F, Elena K, et al. Optimizing the diagnosis of chronic granulomatous disease using dihydrorhodamine‐123 assay: Lessons from a large monocentric cohort. Cytometry Part B: Clinical Cytometry. 2026. doi:10.1002/cytob.70014

BibTeX
@article{Oiuna2026,
  author = {Oiuna, Lodoeva and Tatiana, Varlamova and Daria, Yukhacheva and Viktoriia, Vedmedskaia and Mariia, Fadeeva and Elena, Kulakovskaya and Ekaterina, Malakhova and Elvira, Musaeva and Elizaveta, Samykina and Tatiana, Sozonova and Svetlana, Glushkova and Mariia, Igonina and Andrey, Russiyanov and Varvara, Brilliantova and Maxim, Alexenko and Svetlana, Vahliarskaya and Elena, Raykina and Yulia, Rodina and Michael, Maschan and Anna, Shcherbina and Dmitry, Pershin},
  title = {Optimizing the diagnosis of chronic granulomatous disease using dihydrorhodamine‐123 assay: Lessons from a large monocentric cohort},
  journal = {Cytometry Part B: Clinical Cytometry},
  year = {2026},
  doi = {10.1002/cytob.70014}
}
Kostenlos starten →